Viridian Therapeutics, Inc. Common Stock
XNAS:VRDN
32.6
$35.22 - 500.00
$32.19 - 60.00
$31.62
$33.23
$31.9
$31.8
33.34
9.9
2336387
1357839.4
85963654.98
Chart
TendieTensor AI Analysis
Company
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Fundamentals
143
-9.230000
8.325410
100
BBG002H242Z5
BBG002H24301
81.67M
95.37M
Technicals
Short Interest
—
—
—
Higher = harder to cover
—
Prev: —
—
—
5D avg: —
—
Discussion
Login to participate in discussions.
Recent News
Related Stocks
Based on the portfolios of people who own VRDN. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.